DK1288223T3 - Terapeutiske peptidderivater - Google Patents

Terapeutiske peptidderivater

Info

Publication number
DK1288223T3
DK1288223T3 DK02026862T DK02026862T DK1288223T3 DK 1288223 T3 DK1288223 T3 DK 1288223T3 DK 02026862 T DK02026862 T DK 02026862T DK 02026862 T DK02026862 T DK 02026862T DK 1288223 T3 DK1288223 T3 DK 1288223T3
Authority
DK
Denmark
Prior art keywords
peptide derivatives
therapeutic peptide
peptide
amino
amide
Prior art date
Application number
DK02026862T
Other languages
Danish (da)
English (en)
Inventor
Sylviane Moreau
Susan Riley Keyes
John E Taylor
Zhengxin Dong
Sun Hyuk Kim
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of DK1288223T3 publication Critical patent/DK1288223T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
DK02026862T 1993-08-09 1994-08-08 Terapeutiske peptidderivater DK1288223T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10419493A 1993-08-09 1993-08-09
PCT/US1994/008875 WO1995004752A1 (en) 1993-08-09 1994-08-08 Therapeutic peptide derivatives

Publications (1)

Publication Number Publication Date
DK1288223T3 true DK1288223T3 (da) 2005-03-29

Family

ID=22299154

Family Applications (3)

Application Number Title Priority Date Filing Date
DK94924590T DK0788509T3 (da) 1993-08-09 1994-08-08 Terapeutiske peptidderivater
DK02026862T DK1288223T3 (da) 1993-08-09 1994-08-08 Terapeutiske peptidderivater
DK02026863T DK1288224T3 (da) 1993-08-09 1994-08-08 Terapeutiske peptidderivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK94924590T DK0788509T3 (da) 1993-08-09 1994-08-08 Terapeutiske peptidderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02026863T DK1288224T3 (da) 1993-08-09 1994-08-08 Terapeutiske peptidderivater

Country Status (29)

Country Link
US (1) US5552520A (cs)
EP (3) EP0788509B1 (cs)
JP (3) JP3618750B2 (cs)
KR (1) KR100325972B1 (cs)
CN (1) CN1055700C (cs)
AT (3) ATE284413T1 (cs)
AU (1) AU689490B2 (cs)
CA (1) CA2168113C (cs)
CZ (3) CZ292586B6 (cs)
DE (3) DE69432758T2 (cs)
DK (3) DK0788509T3 (cs)
ES (3) ES2196031T3 (cs)
FI (1) FI960584L (cs)
GE (1) GEP20002146B (cs)
HU (1) HU224350B1 (cs)
LT (1) LT4078B (cs)
LV (1) LV11549B (cs)
MD (1) MD1591B2 (cs)
NZ (1) NZ271238A (cs)
PL (1) PL180612B1 (cs)
PT (2) PT788509E (cs)
RO (1) RO117259B1 (cs)
RU (1) RU2133252C1 (cs)
SG (1) SG75092A1 (cs)
SI (2) SI9420051A (cs)
SK (1) SK15096A3 (cs)
UA (1) UA44707C2 (cs)
WO (1) WO1995004752A1 (cs)
ZA (1) ZA945966B (cs)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
EP0770623A4 (en) * 1995-03-20 2002-07-31 Kyowa Hakko Kogyo Kk INNOVATIVE CALCITON DERIVATIVES
US5824772A (en) * 1995-04-04 1998-10-20 Advanced Bioconcept, Inc. Fluorescent somatostatin
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6479457B2 (en) 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US7078413B2 (en) 1996-04-19 2006-07-18 Wisconsin Alumni Research Foundation Compositions and methods of use for a bombesin peptide
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
JP4041311B2 (ja) * 1999-06-25 2008-01-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチンアゴニスト
DE60027334T2 (de) * 1999-08-18 2007-03-29 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Zusammensetzung mit verzögerter Abgabe in der ein Peptid mit einem Polymer komplexiert ist
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
AU2004200688B2 (en) * 1999-08-18 2007-01-25 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
US7109166B1 (en) * 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
MD2074G2 (ro) * 2000-12-29 2003-06-30 Юрий НИКИТИН Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată
WO2002070555A2 (en) 2001-03-06 2002-09-12 Il Consorzio Ferrara Richerche Method of modulating the proliferation of medullary thyroid carcinoma cells
JP4204322B2 (ja) * 2001-03-08 2009-01-07 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアンタゴニスト
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
FR2833596B1 (fr) * 2001-12-14 2005-02-18 Aventis Pharma Sa Procede de preparation de derives d'echinocandine
US20040171070A1 (en) * 2002-05-20 2004-09-02 Ramagauri Bhikhabhai Peptide analysis using a solid support
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004056314A2 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
CN102112145B (zh) 2008-06-12 2014-07-30 辛它可辛有限公司 神经内分泌病的抑制
CA2726092A1 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20120172650A1 (en) * 2009-03-18 2012-07-05 Laurence Katznelson Use of somatostatin or an analogue thereof in combination with external radiation therapy
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
KR101915820B1 (ko) 2010-01-13 2018-11-06 입센 파마 에스.에이.에스 소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
CN108659100A (zh) * 2017-03-28 2018-10-16 上海新生源医药集团有限公司 具有镇痛作用的多肽及其应用
SG11202103586UA (en) 2018-10-11 2021-05-28 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
KR102740870B1 (ko) * 2020-08-05 2024-12-12 주식회사 레미바이오 아스코르브산 유도체 및 이를 포함하는 조성물
CN120329530A (zh) * 2024-01-16 2025-07-18 元素驱动(杭州)生物科技有限公司 含有环酰亚胺结构的聚酯聚合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
HU206890B (en) * 1986-10-13 1993-01-28 Sandoz Ag Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
GB2218102B (en) * 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
DE3910667A1 (de) * 1988-04-11 1989-10-19 Sandoz Ag Peptidderivate
ZA895838B (en) 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
BE1003762A3 (fr) * 1988-11-11 1992-06-09 Sandoz Sa Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives.
ATE131471T1 (de) * 1989-12-22 1995-12-15 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
GB9209032D0 (en) * 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives

Also Published As

Publication number Publication date
EP1288224A1 (en) 2003-03-05
DE69434181D1 (de) 2005-01-13
US5552520A (en) 1996-09-03
ATE399177T1 (de) 2008-07-15
HU9600281D0 (en) 1996-04-29
LV11549B (en) 1997-04-20
EP0788509B1 (en) 2003-05-28
AU689490B2 (en) 1998-04-02
AU7481994A (en) 1995-02-28
SI9420051A (en) 1996-12-31
MD1591B2 (ro) 2001-01-31
CN1055700C (zh) 2000-08-23
CA2168113A1 (en) 1995-02-16
EP0788509A1 (en) 1997-08-13
HK1053313A1 (en) 2003-10-17
MD960137A (en) 1999-01-31
JP2004339237A (ja) 2004-12-02
SI0788509T1 (en) 2003-10-31
EP0788509A4 (en) 1999-07-14
CZ39096A3 (en) 1996-11-13
DK0788509T3 (da) 2003-06-23
JP3785179B2 (ja) 2006-06-14
JP3618750B2 (ja) 2005-02-09
EP1288224B1 (en) 2008-06-25
EP1288223B1 (en) 2004-12-08
ATE284413T1 (de) 2004-12-15
SK15096A3 (en) 1996-07-03
HUT73491A (en) 1996-08-28
JP2005015488A (ja) 2005-01-20
WO1995004752A1 (en) 1995-02-16
DE69435105D1 (de) 2008-08-07
JP3869439B2 (ja) 2007-01-17
LT4078B (en) 1996-12-27
PL312989A1 (en) 1996-05-27
LT96025A (en) 1996-07-25
NZ271238A (en) 1997-10-24
RO117259B1 (ro) 2001-12-28
ES2309131T3 (es) 2008-12-16
HK1053314A1 (en) 2003-10-17
FI960584A7 (fi) 1996-02-08
CZ289590B6 (cs) 2002-02-13
PL180612B1 (pl) 2001-03-30
PT1288223E (pt) 2005-03-31
FI960584A0 (fi) 1996-02-08
EP1288223A1 (en) 2003-03-05
DE69432758T2 (de) 2004-02-19
ES2229045T3 (es) 2005-04-16
CN1133047A (zh) 1996-10-09
ES2196031T3 (es) 2003-12-16
GEP20002146B (en) 2000-06-25
DE69432758D1 (en) 2003-07-03
JPH09501177A (ja) 1997-02-04
CZ292586B6 (cs) 2003-10-15
FI960584L (fi) 1996-02-08
RU2133252C1 (ru) 1999-07-20
ATE241643T1 (de) 2003-06-15
SG75092A1 (en) 2000-09-19
LV11549A (lv) 1996-10-20
CA2168113C (en) 2002-10-01
ZA945966B (en) 1995-06-26
UA44707C2 (uk) 2002-03-15
CZ289552B6 (cs) 2002-02-13
DK1288224T3 (da) 2008-10-13
DE69434181T2 (de) 2005-12-01
KR100325972B1 (ko) 2002-07-27
HU224350B1 (hu) 2005-08-29
PT788509E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
DK0788509T3 (da) Terapeutiske peptidderivater
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ES2082003T3 (es) Deshidrodidemnina b.
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
ATE278710T1 (de) Antimikrobiell wirksame peptide
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
BR9813817A (pt) Análogos de hemiasterlina
ATE110742T1 (de) Peptid-verbindungen.
EA199800380A1 (ru) Антагонисты рецептора возбуждающих аминокислот
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
ATE90359T1 (de) Peptide.
RU94014631A (ru) Производные 4-хиномиодигидропиридина, смесь их изомеров или отдельные изомеры и их соли
RU95119704A (ru) Иммуностимулятор и препарат на его основе
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина
DE68908958D1 (de) Peptide.
IT1216096B (it) L_piroglutamil_l_cisteina, dipeptide ad elevata attivita'anticatarattogena e composizioni farmaceutiche che lo contengono.
DE3682368D1 (de) Mitogene peptide.
MX9303606A (es) Derivados de azabicicloheptano n-sustituidos, su obtencion y uso.
NO900255L (no) Peptider med t-cellehjelperaktivitet.
MX9909548A (es) Metodos para la reduccion de fibrinogenos.